RxDoctor Payments DataLook up a doctor →

Veena Watwe, MD

Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1417120221

Payments from drug & device makers

$976,000in general payments, 2019–2025

Across 1,483 payments — averaging $658.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$522K
  • AbbVie$293K
  • Abbott$51K
  • Mannkind Corporation$34K
  • Lilly USA, LLC$29K
  • Valeritas, Inc.$12K
  • plus $36K from 54 others
$16,283in research payments, 2019–2025

Across 5 payments — averaging $3256.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Recordati_rare_diseases_inc.$13K
  • Novartis$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis43$521,646
AbbVie36$293,354
Abbott141$50,625
Mannkind Corporation211$33,962
Lilly USA, LLC213$28,541
Valeritas, Inc.22$11,834
Cequr Corporation9$8,594
Shionogi Inc1$5,215
Zealand Pharma US, Inc.15$3,921
Corcept Therapeutics41$2,752
Eli Lilly22$1,734
AstraZeneca(2 entities)72$1,350
Amgen(2 entities)70$1,074
Novo Nordisk51$996
Sanofi-aventis U.S. LLC57$935
Insulet Corporation45$917
Dexcom, Inc.43$912
Boehringer Ingelheim33$524
Bayer28$489
Merck32$484
Intuity Medical Inc23$481
Ascensia Diabetes Care US Inc.9$395
IBSA Pharma Inc.23$377
Amarin Pharma, Inc.17$338
Tandem Diabetes Care, Inc.19$336
Johnson & Johnson12$333
Radius Health, Inc.17$312
Astellas Pharma US Inc11$302
Antares Pharma, Inc.14$251
Xeris Pharmaceuticals, Inc.12$243
Esperion Therapeutics, Inc.12$212
Amneal Pharmaceuticals LLC12$210
BETA Bionics, Inc.7$188
Amphastar Pharmaceuticals, Inc.10$181
Medtronic(2 entities)6$168
Pfizer9$153
Alvogen Inc5$104
Recordati_rare_diseases_inc.5$92
Vivus LLC6$89
Tolmar, Inc.5$81
Sequel Med Tech, LLC2$73
Madrigal Pharmaceuticals2$71
Endo Pharmaceuticals Inc.4$70
Teva Pharmaceuticals USA, Inc.4$70
Averitas Pharma Inc.3$69
Ipsen Biopharmaceuticals, Inc3$65
Amryt Pharma Holdings Ltd3$64
Acerus Pharmaceuticals Corporation3$57
Embecta Corp.2$55
Verity Pharmaceuticals Inc.2$54
Corium, LLC3$45
Kyowa Kirin, Inc.2$45
Shire North American Group Inc2$44
Apollo Endosurgery US Inc1$42
Halozyme Inc2$42
Aytu Biopharma, Inc.3$39
Axsome Therapeutics, Inc.2$36
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$35
Theracosbio, LLC2$32
Currax Pharmaceuticals LLC2$28

How this compares

$976,000 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$139,901
Medicare patients
239
Services billed
3,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →